Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Armel L Batchi-BouyouDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-7323-9894
Duc TranDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0003-2918-8601
Michael RaddatzDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0001-8610-3489
Teng GaoDepartment of Biomedical Informatics, Harvard University, Cambridge, MA.ORCID 0000-0002-0196-689X
Caitlyn VlasschaertDepartment of Medicine, Queen's University, Kingston, ON, Canada.
Brian SharberDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Jie LiuDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-6365-1888
Giulia PetroneDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0003-3166-4355
Irenaeus C C ChanDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
J Scott BeelerDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-1829-1972
Griffen MustionDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0009-0005-5505-5775
Alexander G BickDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Sean M DevlinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Kelly L BoltonDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Funding
The impact of inherited and modifiable risk factors on clonal hematopoiesis and age-related diseaseR01AG088690 · NIA · WASHINGTON UNIVERSITY · PI Kelly Leigh Bolton · 2024 to 2026
$5.9M
Targeting Clonal Hematopoiesis of Indeterminate Potential Using Human GeneticsDP5OD029586 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BICK, ALEXANDER · 2020 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Predictive modeling of clonal hematopoiesis across diverse cohorts. · full record | OpenQuestion